Seeking Alpha

Acura -6.4% AH after providing update for Aversion

  • The FDA has advised Acura (ACUR) that data from its AP-ADF-301 intranasal abuse liability study for its Aversion combo drug is "insufficient to support an intranasal abuse deterrence claim."
  • Acura says its plans for the drug, including "a revised projected timeline" for submitting an NDA, will be determined following a meeting with the FDA.
  • The company adds it's "committed to developing [its] Aversion opiods products."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: